Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2025 (Specific date: April 9, 2025)
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is the submission of Exhibit 99.1, titled "Becoming a substantial holder." This indicates a change in ownership structure where an entity or individual has acquired a significant stake in the company, triggering a reporting requirement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate the substantial holder notice into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 to identify the specific entity or individual that became a substantial holder.
- Determine the exact percentage of voting securities held by the new substantial holder.
- Verify if the substantial holder has any stated intent to influence control or management of the company.
- Check subsequent filings for any related changes in the company's capital structure or governance.